NASDAQ:BIVI BioVie (BIVI) Stock Price, News & Analysis → The “Next Bitcoin”? 10 CENT Crypto Set to Explode (From True Market Insiders) (Ad) Free BIVI Stock Alerts $0.48 0.00 (0.00%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$0.48▼$0.5050-Day Range$0.47▼$1.8952-Week Range$0.45▼$8.69Volume316,995 shsAverage Volume800,879 shsMarket Capitalization$19.35 millionP/E RatioN/ADividend YieldN/APrice Target$8.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get BioVie alerts: Email Address BioVie MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside1,550.2% Upside$8.00 Price TargetShort InterestHealthy2.78% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.86Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.13 out of 5 starsMedical Sector542nd out of 913 stocksPharmaceutical Preparations Industry240th out of 423 stocks 3.3 Analyst's Opinion Consensus RatingBioVie has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageBioVie has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.78% of the outstanding shares of BioVie have been sold short.Short Interest Ratio / Days to CoverBioVie has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BioVie has recently decreased by 25.00%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldBioVie does not currently pay a dividend.Dividend GrowthBioVie does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BIVI. Previous Next 3.3 News and Social Media Coverage News SentimentBioVie has a news sentiment score of 0.86. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.32 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for BioVie this week, compared to 3 articles on an average week.Search InterestOnly 7 people have searched for BIVI on MarketBeat in the last 30 days. This is a decrease of -53% compared to the previous 30 days.MarketBeat Follows10 people have added BioVie to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BioVie insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.80% of the stock of BioVie is held by insiders.Percentage Held by InstitutionsOnly 4.59% of the stock of BioVie is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of BioVie is -0.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioVie is -0.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBioVie has a P/B Ratio of 1.15. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> About BioVie Stock (NASDAQ:BIVI)BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.Read More BIVI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BIVI Stock News HeadlinesApril 25, 2024 | finance.yahoo.comBioVie Presents Data Showing Potential for Bezisterim (NE3107) to Reduce Inflammation and Restore Homeostasis in a Manner Correlated with Alzheimer’s Disease and Biomarker EndpointsApril 25, 2024 | proactiveinvestors.comBioVie presents new data showing lead drug asset may promote healthier agingApril 27, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.April 25, 2024 | globenewswire.comBioVie Presents Data Showing Potential for Bezisterim (NE3107) to Reduce Inflammation and Restore Homeostasis in a Manner Correlated with Alzheimer's Disease and Biomarker EndpointsApril 21, 2024 | americanbankingnews.comBioVie (BIVI) to Release Earnings on MondayApril 19, 2024 | benzinga.comLatest News for BioVie Stock (NASDAQ:BIVI)April 18, 2024 | globenewswire.comBioVie to Present Data Showing How NE3107 Potentially Restores Homeostasis via Specific Genes Associated with Dementia, Metabolism, and InflammationMarch 19, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioVie Inc. of Class Action Lawsuit and Upcoming Deadlines - BIVIApril 27, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.March 18, 2024 | businesswire.comThe Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioVie Inc. (BIVI)March 17, 2024 | stockhouse.comDEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BioVieMarch 16, 2024 | stockhouse.comINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BioVieMarch 16, 2024 | ca.finance.yahoo.comBIVI Oct 2024 1.500 putMarch 15, 2024 | finance.yahoo.comBIVI Jul 2024 3.500 putMarch 15, 2024 | finance.yahoo.comBIVI Apr 2024 5.000 putMarch 15, 2024 | prnewswire.comShareholders that lost money on BioVie Inc.(BIVI) should contact Levi & Korsinsky about pending Class Action - BIVIMarch 14, 2024 | prnewswire.comThe Gross Law Firm Notifies Shareholders of BioVie Inc. (BIVI) of a Class Action Lawsuit and an Upcoming DeadlineMarch 14, 2024 | stockhouse.com4-DAY DEADLINE ALERT: The Schall Law Firm Encourages Investors in BioVie Inc. with Losses of $100,000 to Contact the FirmMarch 13, 2024 | prnewswire.comBIVI Investors Have Opportunity to Lead BioVie Inc. Securities Fraud LawsuitMarch 12, 2024 | prnewswire.comClass Action Filed Against BioVie Inc. (BIVI) - March 19, 2024 Deadline to Join - Contact Levi & KorsinskyMarch 11, 2024 | proactiveinvestors.comBioVie to kick off Phase 2b trial for lead asset in Parkinson's disease in late-summerMarch 11, 2024 | globenewswire.comBioVie Announces Pipeline Update and Near-Term Clinical PrioritiesMarch 11, 2024 | prnewswire.comBioVie Inc. Class Action: The Gross Law Firm Reminds BioVie Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 19, 2024 - BIVIMarch 9, 2024 | stockhouse.comSHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BioVieMarch 8, 2024 | markets.businessinsider.comBIOVIE INVESTOR ALERT: Kirby McInerney LLP Alerts BioVie, Inc. (BIVI) Investors of Looming Lead Plaintiff Deadline in Class Action LawsuitMarch 7, 2024 | prnewswire.comContact The Gross Law Firm by March 19, 2024 Deadline to Join Class Action Against BioVie Inc.(BIVI)March 7, 2024 | markets.businessinsider.comATTENTION BIOVIE INC. Shareholders: Securities Fraud Lawsuit Filed Against BioVie Inc. (BIVI)See More Headlines Receive BIVI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioVie and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/12/2024Today4/27/2024Next Earnings (Estimated)5/10/2024Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:BIVI CUSIPN/A CIK1580149 Webbioviepharma.com Phone(775) 888-3162FaxN/AEmployees18Year FoundedN/APrice Target and Rating Average Stock Price Target$8.00 High Stock Price Target$11.00 Low Stock Price Target$5.00 Potential Upside/Downside+1,550.2%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-50,260,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-332.18% Return on Assets-137.85% Debt Debt-to-Equity RatioN/A Current Ratio1.47 Quick Ratio1.47 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.42 per share Price / Book1.15Miscellaneous Outstanding Shares39,925,000Free Float38,009,000Market Cap$19.36 million OptionableOptionable Beta0.79 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Cuong Viet Do M.B.A. (Age 58)President, CEO & Director Comp: $1.08MMs. Joanne Wendy Kim CPA (Age 69)CFO, Treasurer & Corporate Secretary Comp: $397.38kDr. Joseph M. Palumbo M.D. (Age 64)Executive VP of R&D and Chief Medical Officer Comp: $722kMr. Clarence N. Ahlem (Age 69)Senior Vice President of Operations Dr. Penelope Markham Ph.D. (Age 58)Senior Vice President of Liver Disease Program Ms. Denise SmithSenior Vice President of Manufacturing & DevelopmentDr. Christopher L. Reading Ph.D. (Age 76)Senior Vice President of Alzheimer's Disease Program Ms. Sarah Overton Hoit (Age 56)Chief Social Impact Officer More ExecutivesKey CompetitorsAptorum GroupNASDAQ:APMAddex TherapeuticsNASDAQ:ADXNAlaunos TherapeuticsNASDAQ:TCRTRenovoRxNASDAQ:RNXTGalectoNASDAQ:GLTOView All CompetitorsInsiders & InstitutionsSimplex Trading LLCSold 30,000 shares on 2/2/2024Ownership: 0.000%Cuong V DoBought 10,000 shares on 11/30/2023Total: $17,800.00 ($1.78/share)Steve GorlinSold 8,560 sharesTotal: $26,108.00 ($3.05/share)Richard J BermanSold 10,805 sharesTotal: $37,817.50 ($3.50/share)Richard J BermanSold 5,984 sharesTotal: $34,767.04 ($5.81/share)View All Insider TransactionsView All Institutional Transactions BIVI Stock Analysis - Frequently Asked Questions Should I buy or sell BioVie stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioVie in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" BIVI shares. View BIVI analyst ratings or view top-rated stocks. What is BioVie's stock price target for 2024? 2 brokers have issued twelve-month target prices for BioVie's stock. Their BIVI share price targets range from $5.00 to $11.00. On average, they anticipate the company's share price to reach $8.00 in the next year. This suggests a possible upside of 1,550.2% from the stock's current price. View analysts price targets for BIVI or view top-rated stocks among Wall Street analysts. How have BIVI shares performed in 2024? BioVie's stock was trading at $1.26 at the beginning of the year. Since then, BIVI stock has decreased by 61.5% and is now trading at $0.4848. View the best growth stocks for 2024 here. Are investors shorting BioVie? BioVie saw a decline in short interest in the month of April. As of April 15th, there was short interest totaling 1,110,000 shares, a decline of 25.0% from the March 31st total of 1,480,000 shares. Based on an average trading volume of 2,540,000 shares, the days-to-cover ratio is presently 0.4 days. View BioVie's Short Interest. When is BioVie's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our BIVI earnings forecast. How were BioVie's earnings last quarter? BioVie Inc. (NASDAQ:BIVI) issued its quarterly earnings results on Monday, February, 12th. The company reported ($0.22) EPS for the quarter, topping analysts' consensus estimates of ($0.32) by $0.10. How do I buy shares of BioVie? Shares of BIVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BIVI) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithBiden out June 13; Kamala won’t replace him?Paradigm PressThe World's First "$20 Trillion Drug?"Behind the MarketsExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioVie Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
